We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
On May 3, just three months after Thailand's unilateral seizure of patent rights to Bristol Myer Squibb's anti-clotting drug Plavix, Brazil followed suit in the first post-WTOTRIPS Agreement decree of compulsory patent license in Latin America, by granting a compulsory license for efavirenz, Merck's reverse transcriptase inhibitor that is the standard-of-care in HIV treatment
